암을 일으킬 것으로 의심됨 (노출되어도 암을 일으키지 않는다는 결정적인 증거가 있는 노출경로가 있다면 노출경로 기재)
발암성 물질
구분 2
경고
P201, P202, P281, P308+P313, P405,P501
H360
태아 또는 생식능력에 손상을 일으킬 수 있음
생식독성 물질
구분 1A, 1B
위험
예방조치문구:
P201
사용 전 취급 설명서를 확보하시오.
P202
모든 안전 조치 문구를 읽고 이해하기 전에는 취급하지 마시오.
P280
보호장갑/보호의/보안경/안면보호구를 착용하시오.
P281
요구되는 개인 보호구를 착용하시오
P308+P313
노출 또는 접촉이 우려되면 의학적인 조치· 조언를 구하시오.
P405
밀봉하여 저장하시오.
P501
...에 내용물 / 용기를 폐기 하시오.
클로로마딘온아세테이트 C화학적 특성, 용도, 생산
개요
Chlormadinone acetate is a synthetic progestin. It binds to progesterone, androgen, and glucocorticoid receptors in vitro (Kis = 2.5, 3.8, and 16 nM, respectively, for the human receptors). Chlormadinone acetate increases the number of endometrial glands and uterine weight in β-estradiol-primed rabbits when administered at a dose of 45 μg/kg per day for five days. Chlormadinone acetate reduces testosterone-induced increases in the seminal vesicle weight of castrated male rats when administered at doses of 4.6 and 21.5 mg/kg per day for eight days.
화학적 성질
Crystalline Solid
용도
Orally active progesteron with antiandrogenic activity; has been used in combinations as an oral contraceptive.
Progestogen; antineoplastic (hormonal)
World Health Organization (WHO)
Chlormadinone acetate, a synthetic progestogen, was introduced
in 1965 as a component in oral contraceptive preparations. In 1967, as a result of
new regulations required by the United States Food and Drug Administration,
chlormadinone acetate was submitted to long-term toxicity studies and by the early
1970s it was shown to be associated with an increased incidence of mammary
tumours in beagle bitches which led to its withdrawal by several regulatory
authorities. Subsequently the validity of the beagle bitch model as a predictor of
carcinogenicity of steroid contraceptives has been contested by many national
regulatory authorities and chlormadinone remains available in some countries for
contraceptive purposes. In some instances it is indicated for treatment of
progesterone deficiency and endometriosis, and of irregular uterine bleeding due
to fibroids.
(Reference: (WHODI) WHO Drug Information, 84.1, 5, 1984)
Safety Profile
Suspected carcinogen
with experimental carcinogenic and
tumorigenic data. Moderately toxic by
intraperitoneal route. Human maternal and
reproductive effects by ingestion,
intramuscular, and possibly other routes:
ovary, uterus, cervix, vagina, and fallopian
tube changes; menstrual cycle changes or
disorders; changes in ferthty; and other
unspecified female effects. A human
teratogen that causes developmental
abnormalities of the endocrine system in the
fetus. Experimental teratogenic and
reproductive effects. An oral contraceptive.
When heated to decomposition it emits
toxic fumes of Cl-.